CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Selumetinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01011933
NCT01011933Phase 2Completed
CompareCT.gov

A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

National Cancer Institute (NCI)·interventional·Posted Nov 11, 2009·Updated Jul 23, 2019

In Brief

A Phase 2 clinical trial evaluating Diagnostic Laboratory Biomarker Analysis and Selumetinib for Endometrial Adenocarcinoma and 3 related conditions. Completed, enrolled 54 participants across 72 sites.

Detailed Summary

This phase II trial is studying how well selumetinib works in treating patients with recurrent or persistent endometrial cancer that has come back or is persistent. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
CountriesUnited States
CollaboratorsNRG Oncology

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 11, 2009
Enrollment StartSep 1, 2009
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 16.6 years ago

Interventions

Diagnostic Laboratory Biomarker Analysisother

Correlative studies

Selumetinibdrug

Given PO